Head and Neck Cancer Update 1 | 2007

You are here: Home: Audio Program Guide: HNCU 1 | 2007 Audio: HNCU 1 | 2007

Go to interview with Edward S Kim, MD
Go to interview with Marshall R Posner, MD
Go to interview with Walter J Curran Jr, MD

To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.


	Edward S Kim, MD Assistant Professor of Medicine Department of Thoracic, Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas
	Click here to download the entire interview

Track 1

Rationale for EGFR-directed therapy in squamous cell cancer of the head and neck (SCCHN)

Track 2

Multidisciplinary management of SCCHN

Track 3

Current integration of cetuximab in the treatment algorithm

Track 4

Ongoing controversy over induction therapy with chemoradiation therapy

Track 5

TAX-323 Phase III study of induction docetaxel/cisplatin/5-fluorouracil (TPF) versus cisplatin/ 5-fluorouracil (PF) followed by radiation therapy alone

Track 6

Tolerability considerations with TPF

Track 7

Demographic heterogeneity among patients with newly diagnosed SCCHN

Track 8

Risk factors for the development of head and neck tumors

Track 9

Predictive and prognostic utility of molecular and clinical markers

Track 10

Investigating dose response with EGFR-directed agents

Track 11

Biologic basis of radiosensitization

Track 12

Quality of life with concurrent cetuximab and radiation therapy

Track 13

Relationship between disease site and treatment response

Track 14

Evolving role of cetuximab in the management of multiple solid tumors

Track 15

EXTREME Phase III study of PF/cetuximab versus PF alone for recurrent or metastatic SCCHN

Track 16

Feasibility studies of induction chemotherapy with cetuximab

Track 17

Emerging clinical trial data with erlotinib in SCCHN

Track 18

Rationale for continued investigation of panitumumab in head and neck cancer

Track 19

Consensus-based management strategies for dermatotoxicity associated with EGFR inhibitors

Track 20

Antimicrobial and anti-inflammatory agents in the prevention of rash


	Marshall R Posner, MD Medical Director, Head and Neck Oncology Program Dana-Farber Cancer Institute Boston, Massachusetts
	Click here to download the entire interview

Track 1

Demographic trends in cancer of the head and neck

Track 2

Evolving prognostic significance of HPV-related tumors of the oropharynx

Track 3

Biology and transmission of HPV-16

Track 4

Distinct clinical presentation of oropharyngeal cancer

Track 5

Impact of cetuximab on the current treatment of SCCHN

Track 6

Clinical trials of oral tyrosine kinase inhibitors (TKIs) targeting EGFR

Track 7

Treatment advances that improve cure rates

Track 8

Primary surgery in the setting of limited metastases

Track 9

Precision and technique with intensity-modulated radiation therapy (IMRT)

Track 10

Incremental contribution of docetaxel in the treatment of SCCHN

Track 11

Selection of systemic versus radiosensitizing platinums

Track 12

Combining EGFR monoclonal antibodies with induction chemotherapy and chemoradiation therapy

Track 13

Utilizing risk-based treatment algorithms

Track 14

Significance of performance status, comorbidities and age in therapy selection

Track 15

Prophylactic and acute management of neutropenia and mucositis with TPF

Track 16

Novel regimens combining TKIs and antibodies

Track 17

Sequencing palliative treatments in progressive metastatic disease

Track 18

End-of-life considerations

Track 19

Local and national mortality trends in head and neck cancer

Track 20

Chemoprevention strategies for viral-linked cancer of the head and neck


	Walter J Curran Jr, MD Professor and Chairman Department of Radiation Oncology Deputy Director for Clinical Sciences Kimmel Cancer Center of Jefferson Medical College Thomas Jefferson University Philadelphia, Pennsylvania
	Click here to download the entire interview